Prospective Longitudinal Trends in Body Composition and Clinical Outcomes 3 Years Following Sleeve Gastrectomy.
Adolescent
Adult
Aged
Body Composition
/ physiology
Female
Follow-Up Studies
Gastrectomy
/ adverse effects
Humans
Longitudinal Studies
Male
Middle Aged
Obesity, Morbid
/ diet therapy
Postoperative Period
Probiotics
/ administration & dosage
Prognosis
Time Factors
Treatment Outcome
Weight Loss
/ physiology
Young Adult
Bariatric surgery
Clinical parameters
Excess weight loss
Fat free mass
Fat mass
Journal
Obesity surgery
ISSN: 1708-0428
Titre abrégé: Obes Surg
Pays: United States
ID NLM: 9106714
Informations de publication
Date de publication:
12 2019
12 2019
Historique:
pubmed:
14
7
2019
medline:
29
5
2020
entrez:
14
7
2019
Statut:
ppublish
Résumé
Longitudinal assessment of body composition following bariatric surgery allows monitoring of health status. Our aim was to elucidate trends of anthropometric and clinical outcomes 3 years following sleeve gastrectomy (SG). A prospective cohort study of 60 patients who underwent SG. Anthropometrics including body composition analysis measured by multi-frequency bioelectrical impedance analysis, blood tests, liver fat content measured by abdominal ultrasound and habitual physical activity were evaluated at baseline and at 6 (M6), 12 (M12), and 36 (M36) months post-surgery. Sixty patients (55% women, age 44.7 ± 8.7 years) who completed the entire follow-up were included. Fat mass (FM) was reduced significantly 1 year post-surgery (55.8 ± 11.3 to 26.7 ± 8.3 kg; P < 0.001) and then increased between 1 and 3 years post-operatively, but remained below baseline level (26.7 ± 8.3 to 33.1 ± 11.1 kg; P < 0.001). Fat free mass (FFM) decreased significantly during the first 6 months (64.7 ± 14.3 to 56.9 ± 11.8 kg; P < 0.001), slightly decreased between M6 and M12 and then reached a plateau through M36. Weight loss "failure" (< 50% excess weight loss) was noticed in 5.0% and 28.3% of patients at M12 and M36, respectively. Markers of lipid and glucose metabolism changed thereafter in parallel to the changes observed in FM, with the exception of HDL-C, which increased continuingly from M6 throughout the whole period analyzed (45.0 ± 10.2 to 59.5 ± 15.4 mg/dl; P < 0.001) and HbA1c which continued to decrease between M12 and M36 (5.5 ± 0.4 to 5.3 ± 0.4%; P < 0.001). There were marked within-person variations in trends of anthropometric and clinical parameters during the 3-year follow-up. Weight regain primarily attributed to FM with no further decrease in FFM occurs between 1 and 3 years post-SG. FM increase at mid-term may underlie the recurrence of metabolic risk factors and can govern clinical interventions.
Sections du résumé
BACKGROUND AND AIMS
Longitudinal assessment of body composition following bariatric surgery allows monitoring of health status. Our aim was to elucidate trends of anthropometric and clinical outcomes 3 years following sleeve gastrectomy (SG).
METHODS
A prospective cohort study of 60 patients who underwent SG. Anthropometrics including body composition analysis measured by multi-frequency bioelectrical impedance analysis, blood tests, liver fat content measured by abdominal ultrasound and habitual physical activity were evaluated at baseline and at 6 (M6), 12 (M12), and 36 (M36) months post-surgery.
RESULTS
Sixty patients (55% women, age 44.7 ± 8.7 years) who completed the entire follow-up were included. Fat mass (FM) was reduced significantly 1 year post-surgery (55.8 ± 11.3 to 26.7 ± 8.3 kg; P < 0.001) and then increased between 1 and 3 years post-operatively, but remained below baseline level (26.7 ± 8.3 to 33.1 ± 11.1 kg; P < 0.001). Fat free mass (FFM) decreased significantly during the first 6 months (64.7 ± 14.3 to 56.9 ± 11.8 kg; P < 0.001), slightly decreased between M6 and M12 and then reached a plateau through M36. Weight loss "failure" (< 50% excess weight loss) was noticed in 5.0% and 28.3% of patients at M12 and M36, respectively. Markers of lipid and glucose metabolism changed thereafter in parallel to the changes observed in FM, with the exception of HDL-C, which increased continuingly from M6 throughout the whole period analyzed (45.0 ± 10.2 to 59.5 ± 15.4 mg/dl; P < 0.001) and HbA1c which continued to decrease between M12 and M36 (5.5 ± 0.4 to 5.3 ± 0.4%; P < 0.001). There were marked within-person variations in trends of anthropometric and clinical parameters during the 3-year follow-up.
CONCLUSIONS
Weight regain primarily attributed to FM with no further decrease in FFM occurs between 1 and 3 years post-SG. FM increase at mid-term may underlie the recurrence of metabolic risk factors and can govern clinical interventions.
Identifiants
pubmed: 31301031
doi: 10.1007/s11695-019-04057-2
pii: 10.1007/s11695-019-04057-2
doi:
Banques de données
ClinicalTrials.gov
['NCT01922830']
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3833-3841Références
Obesity (Silver Spring). 2018 May;26(5):862-868
pubmed: 29604193
Obes Surg. 2015 Dec;25(12):2344-51
pubmed: 25948283
Horm Metab Res. 2015 Nov;47(12):873-9
pubmed: 26134531
Obes Surg. 2018 Oct;28(10):3111-3115
pubmed: 29909510
Obes Surg. 2015 Mar;25(3):443-51
pubmed: 25218013
Obes Surg. 2016 Mar;26(3):479-85
pubmed: 26189734
Surg Obes Relat Dis. 2015 Jan-Feb;11(1):238-47
pubmed: 25547050
World J Gastroenterol. 2016 Jan 14;22(2):681-703
pubmed: 26811617
Nutrition. 2018 Mar;47:1-5
pubmed: 29429527
Scand J Surg. 2019 Mar;108(1):3-9
pubmed: 30187823
AJR Am J Roentgenol. 2009 Apr;192(4):909-14
pubmed: 19304694
Surg Obes Relat Dis. 2018 Jun;14(6):741-747
pubmed: 29625744
Obes Surg. 2010 Nov;20(11):1509-15
pubmed: 20820937
J Endocrinol Invest. 2018 Nov;41(11):1307-1315
pubmed: 29574529
JPEN J Parenter Enteral Nutr. 2017 May;41(4):583-591
pubmed: 26838526
Nutrition. 2014 May;30(5):569-74
pubmed: 24698348
J Gastrointest Surg. 2019 Mar;23(3):445-450
pubmed: 30187324
Surg Obes Relat Dis. 2018 Jun;14(6):803-807
pubmed: 29628405
Obes Surg. 2018 Jun;28(6):1665-1671
pubmed: 29273924
Int J Obes (Lond). 2018 Feb;42(2):147-155
pubmed: 28852205
Surg Obes Relat Dis. 2017 Jan;13(1):101-109
pubmed: 27521254
Obes Surg. 2018 Mar;28(3):649-655
pubmed: 28975492
Obes Surg. 2017 Nov;27(11):2940-2949
pubmed: 28550439
Int J Obes (Lond). 2019 Aug;43(8):1497-1507
pubmed: 30568268
Eur J Clin Nutr. 2017 Mar;71(3):353-357
pubmed: 27966570
Surgery. 2019 Mar;165(3):565-570
pubmed: 30316577
Surg Obes Relat Dis. 2015 May-Jun;11(3):489-506
pubmed: 26093765
Obes Surg. 2014 Dec;24(12):2082-8
pubmed: 24902652
Obes Surg. 2017 Jul;27(7):1735-1740
pubmed: 27885535
Obes Surg. 2016 Apr;26(4):785-96
pubmed: 26205215
Eur J Clin Nutr. 2015 Jan;69(1):3-13
pubmed: 25271012
Obes Surg. 2013 Dec;23(12):1957-65
pubmed: 23856991
Diabetes Metab. 2015 Nov;41(5):416-21
pubmed: 26022386
Obes Surg. 2018 Mar;28(3):864-868
pubmed: 29264782
JAMA Surg. 2015 Nov;150(11):1051-7
pubmed: 26244446
Obes Surg. 2016 Jun;26(6):1326-34
pubmed: 27048439
Obes Surg. 2014 Sep;24(9):1476-80
pubmed: 24464546
Obes Surg. 2016 Aug;26(8):1659-96
pubmed: 27412673
Mayo Clin Proc. 2010 Nov;85(11):1057; author reply 1057-8
pubmed: 21037049
Surg Endosc. 2016 May;30(5):1983-7
pubmed: 26194256
Obes Surg. 2019 Jan;29(1):183-189
pubmed: 30232726
Gastroenterol Res Pract. 2013;2013:256145
pubmed: 24348530
PLoS One. 2016 Sep 09;11(9):e0162603
pubmed: 27612202
Surg Endosc. 2014 Feb;28(2):500-7
pubmed: 24013471
Am Surg. 2015 Aug;81(8):812-5
pubmed: 26215245
Clin Nutr. 2016 Dec;35(6):1308-1314
pubmed: 26948400
Obes Surg. 2018 Dec;28(12):3783-3794
pubmed: 30121858
Obes Surg. 2019 Feb;29(2):406-413
pubmed: 30251098
Int J Obes (Lond). 2017 Sep;41(9):1379-1387
pubmed: 28584299